Healthcare / Medical Instruments & SuppliesNSE
$208.47
-0.41 (-0.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-374.7M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.1B
P/E
77.5x
↑EV/EBITDA
10.5x
↓ROE
2.3%
↑Gross Margin
67.1%
↑Debt/Equity
0.62
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+14.5%
FCF CAGR
—
FCF margin
-1.7%
FCF / Net income
-0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.23B · net income $143.2M · FCF $-71.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.23B | $4.23B | $3.92B | $2.95B | $2.81B |
| Net Income | $143.2M | $143.2M | $297.7M | $426.4M | $807.1M |
| EBITDA | $1.41B | $1.41B | $1.27B | $1.11B | $1.42B |
| EPS | — | — | 5.60 | 8.01 | 15.17 |
| Gross Margin | 67.1% | 67.1% | 67.0% | 68.0% | 72.2% |
| Operating Margin | 5.1% | 5.1% | 12.3% | 21.4% | 37.1% |
| Net Margin | 3.4% | 3.4% | 7.6% | 14.5% | 28.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.62 | 0.62 | 0.54 | 0.44 | 0.19 |
| Current Ratio | 1.01 | 1.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-71.0M | $-71.0M | $-374.7M | $-816.3M | $-1.14B |
| Returns | |||||
| ROE | 2.3% | 2.3% | 4.7% | 7.0% | 14.2% |
| Valuation | |||||
| P/E | 77.50 | 77.50 | 63.77 | 55.19 | 37.21 |
| EV/EBITDA | 10.49 | 10.49 | 17.46 | 23.42 | 21.57 |
| P/B | 1.75 | 1.75 | 3.01 | 3.84 | 5.28 |
| Growth & Yield | |||||
| Revenue Growth | 7.7% | 7.7% | 33.1% | 4.8% | — |
| EPS Growth | — | — | -30.1% | -47.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-45.8%
Start / end P/E
n/dx → n/dx
EPS bridge
5.60 → n/d
Residual
-45.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.